Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children.

The addition of a long acting beta agonist (LABA) to inhaled corticosteroid (ICS) therapy can improve asthma symptoms and reduce exacerbations. The addition of LABA may also have an ICS-sparing effect and permit a reduction in ICS maintenance dose.